Positives

• Fenbendazole has shown binding affinity to SARS-CoV-2 proteins in computational studies, and early preprints suggest possible antiviral effects against beta-coronaviruses, though no clinical trials in Long COVID patients have been completed MDPI.
  
  

Negatives

• Real-world impact of fenbendazole on patient outcomes remains unclear: laboratory studies show effects in petri dishes, but animal studies show almost no benefit when used alone, and patients self-administering veterinary fenbendazole have reported inflammation and liver damage CancerChoices.
• Prominent fenbendazole “success stories” often omit that the patient was simultaneously enrolled in immunotherapy trials, leaving the apparent benefit unattributable to the drug alone Anticancer Fund.

Hurdles & Side Effects

• Fenbendazole is approved only for veterinary use and has not been tested in clinical trials for Long COVID. Any use in humans is off-label and should be discussed with a physician.